|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
127,470,000 |
Market
Cap: |
1.89(B) |
Last
Volume: |
639,983 |
Avg
Vol: |
1,080,540 |
52
Week Range: |
$11.665 - $20.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
6,112 |
8,699 |
11,368 |
11,368 |
Total Sell Value |
$97,579 |
$136,292 |
$185,375 |
$185,375 |
Total People Sold |
1 |
2 |
2 |
2 |
Total Sell Transactions |
1 |
2 |
3 |
3 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Van Oort Douglas M |
Chairman and CEO |
|
2014-03-12 |
4 |
A |
$1.05 |
$393,750 |
I/I |
375,000 |
187,500 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2014-02-07 |
4 |
A |
$0.75 |
$62,500 |
I/I |
83,333 |
212,745 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-12-24 |
4 |
GD |
$3.60 |
$55,310 |
D/D |
15,364 |
331,251 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-17 |
4 |
S |
$3.74 |
$2,416 |
D/D |
(646) |
18,439 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-12 |
4 |
S |
$3.68 |
$20,877 |
D/D |
(5,673) |
19,085 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-11 |
4 |
S |
$3.70 |
$74,000 |
D/D |
(20,000) |
24,758 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-10 |
4 |
S |
$3.70 |
$370 |
D/D |
(100) |
44,758 |
|
- |
|
Cardoza George |
Chief Financial Officer |
|
2013-12-09 |
4 |
S |
$3.66 |
$73,200 |
D/D |
(20,000) |
51,089 |
|
- |
|
Cardoza George |
Chief Financial Officer |
|
2013-12-09 |
4 |
A |
$1.55 |
$31,000 |
D/D |
20,000 |
71,089 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-05 |
4 |
S |
$3.67 |
$121,095 |
D/D |
(32,996) |
44,858 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-03 |
4 |
S |
$3.68 |
$81,497 |
D/D |
(22,146) |
77,854 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-02 |
4 |
S |
$3.63 |
$36,422 |
D/D |
(10,000) |
100,000 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-12-02 |
4 |
A |
$0.25 |
$25,000 |
D/D |
100,000 |
110,000 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-11-25 |
4 |
S |
$3.58 |
$15,781 |
D/D |
(4,408) |
3,500,000 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-11-25 |
4 |
S |
$3.58 |
$85,351 |
I/I |
(23,841) |
3,504,408 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-11-22 |
4 |
S |
$3.58 |
$303,620 |
I/I |
(84,720) |
3,528,249 |
|
- |
|
Ross Steven A |
CIOOfficer |
|
2013-11-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,500 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-07-01 |
4 |
GD |
$3.98 |
$10,746 |
I/I |
2,700 |
32,157 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-05-02 |
4 |
S |
$3.60 |
$9,000 |
D/D |
(2,500) |
10,000 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-05-01 |
4 |
S |
$3.56 |
$26,700 |
D/D |
(7,500) |
12,500 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-04-30 |
4 |
S |
$3.75 |
$18,750 |
D/D |
(5,000) |
20,000 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-04-30 |
4 |
S |
$3.65 |
$224,632 |
I/I |
(61,543) |
3,612,969 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-04-29 |
4 |
S |
$3.80 |
$95,000 |
D/D |
(25,000) |
25,000 |
|
- |
|
Gasparini Robert P |
Chief Science Officer |
|
2013-04-29 |
4 |
A |
$0.25 |
$12,500 |
D/D |
50,000 |
50,000 |
|
- |
|
Aspen Select Healthcare Lp |
Executive VP of Finance |
|
2013-04-29 |
4 |
S |
$3.81 |
$146,521 |
I/I |
(38,457) |
3,674,512 |
|
- |
|
544 Records found
|
|
Page 19 of 22 |
|
|